Trending Topics in Gastroenterology | GastroAGI

Predicting endoscopic hemostasis failure in esophageal variceal bleeding

The study aimed to develop and validate a predictive nomogram for assessing the risk of endoscopic hemostasis failure in cirrhotic patients presenting with acute esophagogastric variceal bleeding (EGVB). EGVB is a severe complication of portal hypertension, with a high mortality rate, especially if endoscopic hemostasis fails. Conducted as a retrospective single-center study, 296 patients treated between January 2020 and February 2025 were analyzed. Patients were divided into successful (n=273) and failed (n=23) endoscopic hemostasis groups, with failure defined as rebleeding within five days or inability to control hemorrhage per Baveno VII criteria. Four independent predictors of failure were identified: Shock Index (SI > 1.2), Red Color (RC) sign, active bleeding during endoscopy, and Child-Turcotte-Pugh (CTP) score. Using LASSO regression and multivariate logistic regression, a nomogram was developed with the formula: Logit (P) = −3.548 + 1.695×SI + 2.303×RC sign + 1.785×Active bleeding + 0.46×CTP score. The nomogram demonstrated excellent predictive performance with an AUC of 0.890, outperforming traditional scoring systems like CTP, MELD, and Rockall. Risk stratification classified patients into low, medium, and high-risk categories, with failure rates of 0%, 5.7%, and 19.2%, respectively. High-risk patients require ICU-level monitoring and immediate interventions such as secondary endoscopy, balloon tamponade, or TIPS in case of rebleeding. The study highlights the importance of hemodynamic stability (SI), endoscopic findings (RC sign and active bleeding), and liver function (CTP score) in predicting failure. While the nomogram showed promising results, the study’s single-center retrospective design limits external validation. Future research should incorporate imaging modalities and AI-driven analysis for enhanced precision.

Purastat and its role Upper GI bleeding

Purastat is an innovative and promising hemostatic agent specifically designed for the management of upper gastrointestinal bleeding (UGIB), particularly non-variceal UGIB. It is a synthetic peptide-based gel that belongs to the class of self-assembling peptide hydrogels. Its novel mechanism of action and clinical applications make it a valuable tool for addressing bleeding in challenging scenarios where conventional methods may fail. ### **Role of Purastat in Upper GI Bleeding:** #### **Mechanism of Action:** Purastat works by forming a nanofiber hydrogel when exposed to physiological conditions. This hydrogel provides multiple benefits at the bleeding site: 1. **Physical Hemostasis:** The hydrogel forms a physical barrier over the bleeding site, effectively preventing further blood loss and promoting clot formation. 2. **Platelet Aggregation:** It acts as a scaffold to facilitate platelet aggregation and stabilize clots. 3. **Mucosal Protection:** By covering the bleeding site, it protects the underlying tissue from further damage caused by gastric acid or mechanical forces, which aids in healing. #### **Clinical Applications in UGIB:** Purastat is primarily used in endoscopic procedures to manage **non-variceal upper gastrointestinal bleeding (NVUGIB)**. It has demonstrated efficacy in controlling bleeding from various causes, including: 1. **Peptic Ulcers:** - Active bleeding from gastric or duodenal ulcers. - Bleeding associated with adherent clots or visible blood vessels in ulcers. 2. **Post-Endoscopic Procedures:** - Used as an adjunct to prevent rebleeding after interventions such as thermal coagulation or hemoclip application. 3. **Other Causes of UGIB:** - Bleeding from malignancies, radiation-induced ulcers, or post-surgical sites. #### **Advantages of Purastat in UGIB:** 1. **Ease of Application:** - Purastat is delivered through an endoscope using a catheter, making it minimally invasive and easy to apply directly to the bleeding site. 2. **Rapid Hemostasis:** - It has shown to quickly stop bleeding in challenging cases, even when conventional methods fail. 3. **Safety Profile:** - Purastat is biocompatible and biodegradable, meaning it is well-tolerated without significant adverse effects. It has minimal systemic absorption, reducing the risk of systemic side effects. 4. **Potential for Prophylaxis:** - Purastat has been explored for use in preventing bleeding in high-risk patients, such as those undergoing endoscopic procedures or with recurrent bleeding risks. #### **Limitations:** 1. **Cost:** - Purastat is relatively expensive compared to conventional hemostatic methods, which may limit its accessibility, especially in resource-limited settings. 2. **Limited Evidence Base:** - While initial studies and trials have shown promising results, long-term data and large-scale randomized controlled trials are needed to fully establish its efficacy and cost-effectiveness. 3. **Restricted Indications:** - Currently, Purastat is primarily used for non-variceal UGIB. Its role in managing **variceal bleeding** is not established. ### **Clinical Evidence:** 1. **Randomized Controlled Trials:** Studies have shown Purastat's effectiveness in achieving hemostasis in cases of non-variceal UGIB, particularly in peptic ulcers with active bleeding or stigmata of hemorrhage. 2. **Meta-Analyses:** Systematic reviews suggest that Purastat reduces the need for additional endoscopic interventions and lowers rebleeding rates when used as an adjunctive therapy. 3. **Real-World Applications:** Case reports and series highlight its successful use in refractory bleeding cases, such as bleeding from malignancies or other challenging lesions. ### **Clinical Guidelines:** While Purastat is not yet universally included in major guidelines for UGIB management (e.g., ACG, ESGE, or ASGE), it is recognized as a promising adjunct for cases of refractory bleeding or when conventional methods fail. As more evidence emerges, it may become a standard part of UGIB management protocols. ### **Summary:** Purastat represents a significant advancement in the management of UGIB, offering rapid and effective hemostasis in cases of non-variceal bleeding. Its innovative mechanism of action, ease of application, and favorable safety profile make it a valuable tool, especially for challenging or refractory cases. However, its high cost and limited evidence base remain barriers to widespread adoption. As more clinical trials and real-world studies are conducted, Purastat is likely to play an increasingly important role in UGIB management. ### **Key Takeaways:** - **Indication:** Primarily used for non-variceal UGIB (e.g., peptic ulcer bleeding, post-endoscopic procedures). - **Mechanism:** Self-assembling peptide hydrogel creates a physical barrier, facilitates clot stabilization, and protects the mucosa. - **Advantages:** Rapid hemostasis, ease of use, biocompatibility, and low systemic side effects. - **Limitations:** High cost and limited evidence compared to traditional methods. - **Future Potential:** May be incorporated into clinical guidelines as more evidence emerges. Purastat is an exciting development in the field of gastroenterology, offering hope for better outcomes in the management of upper gastrointestinal bleeding.

Traction techniques in endoscopic submucosal dissection (ESD)

Traction techniques in endoscopic submucosal dissection (ESD) play a crucial role in improving procedural outcomes, safety, and feasibility, particularly in Western settings where ESD adoption has faced challenges. These techniques act as a mechanical "third hand" during the procedure, providing consistent countertraction to enhance visualization and facilitate dissection of the submucosal layer. Below is a detailed overview of traction techniques in ESD: ### **Challenges in ESD** - **Longer operating times:** ESD is technically demanding and often requires prolonged procedural time, especially in Western centers where expertise is still developing. - **Higher complication rates:** Without adequate traction, the risk of complications such as perforation increases, particularly in challenging anatomical locations like the esophagus and colon. - **Steep learning curve:** ESD requires advanced skills, and Western practitioners often face difficulties in mastering the technique compared to their Eastern counterparts, where ESD is more widely practiced. ### **Role of Traction Techniques** Traction techniques address these challenges by improving visibility of the submucosal layer and providing better control during dissection. They help reduce procedure time, improve resection rates, and lower complication risks. Key benefits include: 1. **Enhanced visualization:** Traction creates tension on the tissue, exposing the submucosal layer for safer and more precise dissection. 2. **Efficiency:** By facilitating dissection, traction reduces procedure time by approximately 20 minutes, as demonstrated in meta-analyses. 3. **Safety:** Traction techniques lower the risk of perforation, particularly in anatomically difficult areas, by improving operator control. 4. **Improved outcomes:** They increase R0 resection rates, ensuring complete removal of lesions with clear margins. ### **Types of Traction Techniques** Several traction methods have been developed, each with unique advantages. These include: 1. **Clip-with-Line Method:** - A clip is attached to the lesion along with a suture or line, which is externally manipulated to provide traction. - Simple and cost-effective, but requires additional coordination between the operator and assistant. 2. **Clip-and-Snare Technique:** - A snare is used in combination with a clip to pull the tissue and expose the submucosal layer. - Effective in providing dynamic traction but may be more challenging to maneuver. 3. **Internal Elastic Devices:** - Devices like rubber bands or elastic threads are used to provide continuous traction. - These are particularly useful in sites with limited working space. 4. **Double-Scope Systems:** - A second endoscope is introduced to assist with providing traction. - While effective, this method requires additional equipment and personnel, making it less feasible in routine practice. 5. **Single-Operator Traction Tools:** - Newer tools designed for single-operator use provide consistent traction without the need for external assistance. - These innovations are particularly promising for simplifying the procedure and improving efficiency. ### **Evidence Supporting Traction Techniques** - **Meta-analyses:** Studies demonstrate that traction-assisted ESD reduces procedure times, increases R0 resection rates, and lowers perforation risks. - **Western Data:** Although limited, emerging evidence from Western centers shows that selective use of traction techniques yields outcomes comparable to those reported in Eastern studies. - **Technical Challenges:** Traction techniques are especially beneficial in anatomically difficult sites like the esophagus and colon, where visualization and access are more challenging. ### **Importance in Western Practice** In Western settings, the adoption of traction-assisted ESD is particularly valuable due to the barriers mentioned earlier. Expert centers emphasize the need for endoscopists to become proficient with multiple traction techniques to adapt to diverse anatomical and procedural challenges. This versatility helps shorten the learning curve and improve procedural success rates. ### **Conclusion** Traction techniques represent a practical and effective strategy to enhance the safety, efficiency, and outcomes of ESD. By addressing challenges such as visualization, procedural time, and complication risks, these methods support broader adoption of ESD in Western clinical practice. As newer traction tools and devices continue to emerge, their role in refining ESD techniques and expanding accessibility is likely to grow further.

Predicting mortality and readmission in UGIB

This study aimed to assess the accuracy of three pre-endoscopic scoring systems—Glasgow-Blatchford Score (GBS), AIMS65, and pre-endoscopic Rockall Score (pRS)—in predicting 30-day mortality and hospital readmission in patients with upper gastrointestinal bleeding (UGIB) in Iranian tertiary hospitals. Conducted prospectively between April 2024 and April 2025, the study included 290 patients presenting with UGIB symptoms such as hematemesis, melena, syncope, and coffee-ground vomiting. Most patients had severe comorbidities like hepatic failure, malignancy, or heart disease, contributing to a high 30-day mortality rate of 23.4%. Among the scoring systems, the pre-endoscopic Rockall Score (pRS) showed the highest predictive accuracy for mortality (AUROC 0.815) and readmission (AUROC 0.605). AIMS65 also performed well for mortality prediction (AUROC 0.813) but was less effective for readmission (AUROC 0.548). The Glasgow-Blatchford Score (GBS) demonstrated moderate predictive ability for mortality (AUROC 0.762) and was primarily useful for identifying low-risk patients needing early discharge. Low-risk thresholds for the scoring systems—pRS < 1, GBS < 2, and AIMS65 < 1—achieved high sensitivity and negative predictive value (NPV), with pRS showing the best balance (sensitivity 95.4%, NPV 87.5%). This highlights its utility in safely identifying patients for early discharge. Laboratory findings such as low hemoglobin and albumin levels and high blood urea nitrogen (BUN) and INR values were strongly associated with mortality, emphasizing the importance of biochemical and hemodynamic parameters. The study concluded that pRS is the most effective tool for predicting mortality and readmission, supporting its use for risk stratification and resource optimization in emergency settings. However, results may not generalize to non-tertiary care settings, and newer risk models were not evaluated due to resource constraints.

Efficacy of 200 mg vs 1200 mg Simethicone with 3 L PEG for Afternoon Colonoscopy.

This study compared the effectiveness of 200 mg versus 1200 mg simethicone (SIM) added to 3 L polyethylene glycol electrolyte solution (PEG-ELS) for afternoon colonoscopy preparation. Conducted at Shenzhen People’s Hospital between February and July 2024, the randomized, endoscopist-blinded trial included 668 participants. Both groups consumed their bowel preparation between 9:00–11:00 AM for colonoscopies performed 4–6 hours later. The primary outcome was bowel preparation adequacy, measured by the Boston Bowel Preparation Scale (BBPS). Both doses achieved comparable results: 95.8% adequate preparation for 200 mg versus 97.6% for 1200 mg. Secondary outcomes, such as mucosal visibility (Bubble Scale score), adenoma detection rate (ADR), and polyp detection, were statistically similar. Subgroup analysis showed slightly higher right-colon adenoma detection with 1200 mg SIM, but this did not affect overall ADR. Adverse effects like nausea and bloating were slightly lower in the 200 mg group, and both doses had high patient acceptability. The 200 mg dose, costing $1 compared to $6 for 1200 mg, offers significant cost savings without compromising efficacy. The study concludes that 200 mg SIM is a safe, effective, and economical choice for afternoon colonoscopy preparation, pending validation in broader populations.

A new horizon of endoscopic anti-reflux therapy

The new horizon of endoscopic anti-reflux therapy is exemplified by the emergence of Anti-Reflux Mucosal (ARM) interventions, which include anti-reflux mucosectomy (ARMS), mucosal ablation (ARMA), and mucoplasty (ARMP). These techniques represent a groundbreaking advancement in the minimally invasive treatment of gastroesophageal reflux disease (GERD), particularly for patients who remain symptomatic despite pharmacologic therapy. ARM therapies aim to bridge the gap between long-term acid suppression with medications and invasive surgical options like Nissen fundoplication. ### Key Features and Innovations in Endoscopic Anti-Reflux Therapy: 1. **Rationale for Development**: - GERD is a prevalent condition, and approximately 30–40% of patients continue to experience symptoms despite the use of proton pump inhibitors (PPIs) or potassium-competitive acid blockers (PCABs). - ARM techniques were developed to provide a cost-effective, incisionless, and minimally invasive alternative for patients with drug-refractory GERD who do not have large hiatal hernias or major esophageal motility disorders. 2. **Mechanism of Action**: - ARM procedures rely on mucosal removal or modification to induce ulceration, followed by controlled healing at the gastroesophageal junction (GEJ). This healing process leads to shrinkage and tightening of the GEJ, reconstructing the natural mucosal flap valve and enhancing its anti-reflux barrier function. 3. **Specific Techniques**: - **Anti-Reflux Mucosectomy (ARMS)**: Involves mucosal resection to induce controlled scarring and tightening of the GEJ. Long-term data show symptom improvement in 68–81% of patients and PPI discontinuation in 42%. - **Anti-Reflux Mucosal Ablation (ARMA)**: A simpler variant of ARMS that uses argon plasma coagulation instead of resection. It achieves clinical response rates exceeding 70% with measurable improvements in reflux metrics. - **Anti-Reflux Mucoplasty (ARMP)**: A more advanced technique that closes mucosal defects during the initial session, providing immediate anti-reflux effects and reducing risks of delayed ulcer healing or bleeding. 4. **Technical Innovations**: - Tools such as prong clips, loop-assisted systems, and hand suturing have enabled full-thickness closure, involving mucosa, submucosa, and muscle fibers, to reinforce the anti-reflux flap valve. - The development of the "angle booster" accessory improves endoscopic access and visualization of the cardia, enhancing procedural precision. - The counter-mucosal incision technique prevents dehiscence during mucosal closure, ensuring durable valve tightening. 5. **Clinical Outcomes**: - ARM interventions have demonstrated success rates of 70–82% in terms of symptom relief and PPI discontinuation. - Minor complications, such as transient dysphagia (11%) and bleeding (5%), are typically manageable endoscopically, with no major life-threatening complications reported in meta-analyses. 6. **Comparative Effectiveness**: - ARM techniques show comparable efficacy to radiofrequency ablation and Nissen fundoplication, with the added benefits of shorter recovery times, reduced postoperative discomfort, and lower costs. - ARMP provides controlled tightening and immediate symptom relief, making it a preferred option for patients with naïve anatomy, while ARMA is suited for redo cases or patients with submucosal fibrosis. 7. **Application Beyond GERD**: - The mucoplasty principle is being explored for other gastrointestinal conditions, such as treating multiple Schatzki’s rings. This represents the first functional "endoscopic plastic surgery" approach in gastrointestinal disease. 8. **Future Directions**: - Research is focusing on the long-term durability of ARM techniques, standardization of ulcer dimensions for optimal tightening, incorporation of full-thickness suturing, and cost-effectiveness comparisons with surgical options like Nissen fundoplication and magnetic sphincter augmentation. ### Conclusion: Endoscopic anti-reflux therapy, particularly ARM interventions, has redefined the treatment landscape for GERD. These techniques offer a minimally invasive, anatomy-tailored approach that provides significant symptom relief (70–82%) with minimal complications. By addressing the limitations of pharmacologic therapy and offering an alternative to surgery, ARM therapies represent a promising new horizon in the individualized management of GERD.

ERCP Complications

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a critical therapeutic procedure for managing pancreaticobiliary diseases, but it is associated with significant risks. Below is a detailed overview of ERCP complications, including their incidence, risk factors, prevention strategies, and management: --- ### **1. Post-ERCP Pancreatitis (PEP):** - **Incidence:** - Occurs in ~5% of unselected patients. - Increases to ~15% in high-risk patients. - Severe PEP occurs in <1% of cases but can result in significant morbidity and occasional mortality. - **Risk Factors:** - Repeated cannulation attempts. - Pancreatic duct injection. - Sphincter of Oddi dysfunction. - Female sex, younger age, and history of recurrent pancreatitis. - **Prevention:** - Universal prophylaxis with rectal NSAIDs (indomethacin or diclofenac), reducing the risk by 50%. - Aggressive intravenous hydration with lactated Ringer’s solution due to its anti-inflammatory and microcirculatory benefits. - Prophylactic pancreatic stent placement (PSP) in high-risk patients, particularly when combined with NSAIDs. - Technical measures such as guidewire-assisted cannulation, early transition to precut sphincterotomy, and avoiding aggressive pancreatic duct contrast injection. --- ### **2. Bleeding (Postsphincterotomy Bleeding):** - **Incidence:** - Occurs in 1–2% of ERCP procedures, primarily after sphincterotomy. - **Risk Factors:** - Cholangitis, anticoagulation, thrombocytopenia, and chronic renal disease. - **Prevention and Management:** - Proper management of anticoagulants before and after ERCP. - Intraprocedural bleeding can often be controlled with epinephrine injection or balloon tamponade. - Persistent bleeding may require endoscopic therapy using clips, thermal probes, or fully covered self-expanding metal stents (fcSEMS). --- ### **3. Perforation:** - **Incidence:** - Rare, occurring in 0.1–0.6% of cases. - Can result from sphincterotomy, dilation, or guidewire trauma. - **Management:** - Early recognition during the procedure is critical. - Small or retroperitoneal perforations can often be managed endoscopically using clips, sutures, or stents. - Larger or delayed perforations may require surgical repair or drainage, particularly if associated with peritonitis or systemic infection. --- ### **4. Infection:** - **Types:** - **Cholangitis:** The most common infectious complication, occurring in 0.5–3% of cases. - **Cholecystitis:** Can occur days after ERCP, especially following metallic stent placement. - **Risk Factors:** - Incomplete biliary drainage. - Hilar obstruction. - Contaminated duodenoscopes. - **Prevention:** - Prophylactic antibiotics in high-risk situations (e.g., hilar obstruction or incomplete drainage). - Use of single-use or fully sterilizable duodenoscopes to reduce duodenoscope-associated infections. - **Management:** - Cholangitis: Antibiotics and ensuring adequate biliary drainage. - Cholecystitis: Managed with antibiotics and drainage (endoscopic or percutaneous) depending on patient stability. --- ### **5. Duodenoscope-Associated Infections:** - **Cause:** - Contamination of duodenoscopes despite reprocessing efforts. - **Prevention:** - Transition to single-use or fully sterilizable duodenoscopes. - Enhanced reprocessing protocols. --- ### **6. Other Complications:** - **Aspiration Pneumonia:** Rare but possible if patients aspirate during the procedure. - **Cardiopulmonary Complications:** Related to sedation or underlying patient comorbidities. --- ### **Strategies to Minimize ERCP Complications:** 1. **Proper Patient Selection:** - Avoid diagnostic ERCP when less invasive alternatives like Endoscopic Ultrasound (EUS) or Magnetic Resonance Cholangiopancreatography (MRCP) are available. - Reserve ERCP for therapeutic interventions. 2. **Technical Expertise:** - High-volume endoscopists and centers achieve better outcomes and fewer complications. - Centralization of ERCP to specialized units is recommended. 3. **Training and Quality Assurance:** - Use of simulation training, coaching, and report cards to improve operator skill. - Structured debriefing and mentorship programs to address the psychological impact of complications on endoscopists (second victim syndrome). 4. **Early Recognition and Multidisciplinary Management:** - Prompt identification of complications with early CT imaging when perforation or infection is suspected. - Collaboration between gastroenterology, surgery, and radiology teams for optimal rescue management. 5. **Emerging Technologies:** - AI-assisted quality monitoring and augmented reality simulators to improve procedural safety. - Digital endoscopy reporting platforms to standardize complication prevention protocols. --- ### **Conclusion:** While ERCP carries significant risks, advancements in prophylactic strategies, technical refinement, and endoscopic rescue methods have greatly reduced morbidity and mortality. Prevention, early recognition, and expert management of complications are critical to improving patient outcomes.

Endoscopic management of NVNPUB - A Canadian Guideline

The Canadian Association of Gastroenterology (CAG), in collaboration with international experts, has developed evidence-based guidelines specifically for the endoscopic management of nonvariceal, nonpeptic ulcer upper gastrointestinal bleeding (NVNPUB). This guideline addresses bleeding caused by conditions such as malignant tumors, Mallory-Weiss tears (MWTs), Dieulafoy’s lesions (DLs), and gastric antral vascular ectasia (GAVE). Below is a detailed overview of the guidelines: --- ### **Purpose** The guideline provides recommendations to standardize the management of NVNPUB, which has seen an epidemiologic shift in recent years. NVNPUB now accounts for one-third to two-thirds of upper gastrointestinal (GI) bleeding cases, surpassing peptic ulcer bleeding due to a decline in ulcer incidence and a rise in malignancy and vascular-related causes. --- ### **Development and Methodology** - **Origin**: Developed by the CAG with international collaboration and endorsed by major societies such as the American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE), European Society of Gastrointestinal Endoscopy (ESGE), and World Endoscopy Organization (WEO). - **Framework**: Recommendations were formed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology, which evaluates evidence strength and balances benefits against risks. - **Recommendation Classification**: Recommendations are categorized as either strong ("panel recommends") or conditional ("panel suggests") based on the certainty of evidence and balance of effects. --- ### **Key Recommendations for Endoscopic Management** #### **1. Malignant Upper GI Bleeding** - **Preferred Treatment**: The guidelines suggest using topical hemostatic agents (THAs) over conventional endoscopic therapy or no therapy. THAs are associated with better hemostasis and fewer rebleeding events, though the evidence supporting this is of very low certainty. - **Evidence**: TC-325 powder (a THA) demonstrated a lower further bleeding rate (26%) compared to standard therapy (50%), with immediate hemostasis failure in 5% of cases and a 2% adverse event rate. - **Conventional Therapy**: Mechanical methods (e.g., clips), thermal methods (e.g., argon plasma coagulation [APC], bipolar electrocoagulation), and injection therapies (e.g., epinephrine, sclerosants) remain viable but are less effective for diffusely oozing tumors. - **Oncologic Therapy**: Following endoscopic hemostasis, oncologic treatments such as surgery, chemotherapy, or radiation are recommended when feasible. These interventions improve six-month survival rates despite higher toxicity risks. --- #### **2. Mallory-Weiss Tears (MWTs)** - **Active Bleeding**: For spurting or oozing bleeding, endoscopic therapy using endoscopic band ligation (EBL) or through-the-scope clips (TTSC) is recommended over epinephrine injection or no therapy. - **Nonbleeding Stigmata**: For nonbleeding stigmata, the guidelines suggest against intervention. --- #### **3. Dieulafoy’s Lesions (DLs)** - **Preferred Treatment**: Mechanical methods such as EBL or TTSC, or contact thermal coagulation, are preferred over epinephrine injection alone. - **Discouraged Therapy**: Epinephrine injection alone is strongly discouraged due to high rebleeding rates. --- #### **4. Gastric Antral Vascular Ectasia (GAVE)** - **Preferred Treatment**: EBL is suggested over APC due to better outcomes, including fewer transfusion requirements and greater hemoglobin improvement. --- ### **Adverse Events** Endoscopic therapies generally have low complication rates. For topical hemostatic agents, adverse effects occur in approximately 2% of cases, mostly presenting as mild distension or bleeding. --- ### **Research Gaps** The guideline highlights the need for randomized controlled trials (RCTs) comparing THAs with conventional or combined therapies. Additional research is needed to evaluate patient-reported outcomes, cost-effectiveness, and quality of life in NVNPUB management. --- ### **Outcome Priorities** Critical outcomes considered in the guidelines include: - Further bleeding - Rebleeding rates - Hemostasis success - Transfusion requirements - Mortality within 7–30 days --- ### **Certainty of Evidence** Most recommendations are conditional and based on very low certainty due to limited RCTs and heterogeneity in study designs and populations. --- ### **Equity and Feasibility** The accessibility of THAs may pose challenges in low-resource settings. The guidelines emphasize equitable implementation strategies to ensure widespread applicability. --- ### **Patient-Centered Approach** The guidelines encourage shared decision-making tailored to patient-specific factors, such as: - Comorbidities - Severity of bleeding - Treatment goals (comfort vs. aggressive therapy) --- ### **Implementation Value** This guideline offers a global framework for NVNPUB management, aiming to standardize care, improve patient outcomes, and guide local adaptations by healthcare systems. It serves as a critical tool for clinicians managing upper GI bleeding from nonvariceal, nonpeptic ulcer causes. --- In summary, the Canadian guideline for NVNPUB management emphasizes the use of topical hemostatic agents for malignant bleeding, mechanical methods for MWTs and DLs, and endoscopic band ligation for GAVE. It prioritizes patient-centered care and highlights areas for future research to address evidence gaps.

Endoscopic Balloon Dilation in IBD

Endoscopic balloon dilation (EBD) is a minimally invasive procedure used in the management of intestinal strictures in patients with inflammatory bowel disease (IBD), particularly Crohn’s disease (CD). Strictures are areas of narrowing in the gastrointestinal tract caused by inflammation, fibrosis, or a combination of both, which can lead to obstructive symptoms such as abdominal pain, bloating, and difficulty passing stool. EBD aims to widen these narrowed segments, thereby alleviating symptoms, avoiding surgical intervention, and improving patients' quality of life. ### Key Findings from the Study on EBD in IBD: #### 1. **Definition of Difficult EBD**: - EBD procedures were classified as "difficult" if they required more than three dilations per year without achieving satisfactory outcomes. These cases often involved technical challenges and poorer long-term results compared to easier cases. #### 2. **Prevalence**: - Difficult EBD accounted for **54.5%** of all procedures, whereas easier EBDs comprised **45.5%**. #### 3. **Technical Success**: - Easier EBDs achieved **100% surgery-free survival** beyond 12 months, compared to **97.4%** in difficult cases (P = 0.004). Despite good technical success rates, **17.3%** of patients eventually required surgery due to unsuccessful dilation outcomes. #### 4. **Risk Factors for Difficult EBD**: - **Smoking**: The strongest independent predictor of difficult EBD, with an odds ratio (OR) of **4.75** (95% CI 2.78–8.36; P < 0.001). Smoking cessation could significantly improve outcomes. - **Prestenotic Dilation**: Associated with nearly **3-fold higher odds** of difficult EBD (OR 2.79; 95% CI 1.28–6.59; P = 0.013). - **Balloon Diameter**: Smaller balloon sizes increased difficulty — each 1-mm decrease raised the risk (OR 1.21), while larger final diameters were protective (OR 0.68). - **Medication Impact**: - **Adalimumab (ADA)** and **Ustekinumab (UST)** therapies were linked to more difficult EBDs. - **Vedolizumab (VDZ)** and immunosuppressive co-therapy (azathioprine, 6-MP, methotrexate) were associated with easier EBDs and improved outcomes. - **Radiologic Predictors**: - Presence of **multiple strictures** (35% vs 16.8%) and **prestenotic dilation** (14.3% vs 3.3%) were more frequent in difficult cases (P < 0.001). - **Anatomic Pattern**: - Ileocolonic phenotype (L3) and longer stricture lengths were more common in technically difficult dilations. - **Age**: - Younger age was associated with higher likelihood of difficult EBD (P < 0.001), possibly reflecting more aggressive disease behavior. - **Crohn’s Disease Predominance**: - The vast majority of difficult EBDs occurred in Crohn’s disease patients, confirming its fibrostenotic nature. #### 5. **Protective Factors**: - **Vedolizumab (VDZ)**: Demonstrated therapeutic protection and improved outcomes in EBD. - **Immunosuppressive Co-therapy**: Use of azathioprine, 6-MP, or methotrexate was linked to easier EBDs. - **Total Parenteral Nutrition (TPN)**: Showed a significant protective effect (OR 0.13; 95% CI 0.05–0.34; P < 0.001), likely due to its role in promoting mucosal healing. #### 6. **Clinical Implications**: - **Smoking Cessation**: Addressing smoking as a modifiable risk factor could reduce procedural difficulty and improve outcomes. - **Medication Optimization**: Favoring therapies like Vedolizumab or combination immunosuppression may enhance success rates. - **Improved Dilation Techniques**: Using larger balloon diameters and addressing prestenotic dilation could reduce procedural difficulty. - **Tailored Therapy**: Individualized treatment plans based on patient characteristics (e.g., age, disease phenotype, and medication history) could lower surgical rates and healthcare costs. #### 7. **Conclusion**: - More than half of EBD procedures were classified as difficult, often requiring repeat interventions. Optimizing modifiable risk factors, tailoring therapy, and improving procedural techniques may enhance success, reduce surgical rates, and lower healthcare costs. ### Summary of EBD in IBD: EBD represents an effective, surgery-sparing approach for managing strictures in IBD, especially Crohn’s disease. However, certain factors, such as smoking, smaller balloon diameters, and specific medication regimens, increase the risk of procedural difficulty. Protective strategies, including smoking cessation, Vedolizumab therapy, combination immunosuppression, and nutritional support like TPN, can improve outcomes. Careful patient selection and individualized treatment plans are essential to maximize the benefits of EBD while minimizing complications and the need for surgical intervention.

VS System for diagnosing early gastric cancer

### **VS Classification System for Diagnosing Early Gastric Cancer** The **VS Classification System** is a standardized diagnostic approach designed to detect **early gastric cancer (EGC)** using **Narrow Band Imaging (NBI)**, a specialized endoscopic imaging technology. This system enhances the visualization of mucosal and vascular changes in the stomach lining, enabling precise and early detection of cancerous lesions. --- ### **Key Components of the VS Classification System** The VS system is based on the evaluation of two critical features: 1. **Vascular Pattern (V)** 2. **Surface Pattern (S)** These features are assessed using **magnifying endoscopy with NBI**, which provides high-resolution images of the stomach's mucosal and submucosal layers. #### **1. Vascular Pattern (V)** - **Irregular Microvascular Architecture**: - Distorted, tortuous, or dilated capillary structures. - Loss of normal vascular symmetry and organization. - **Demarcation Line**: - A clear boundary separating abnormal vascular patterns from surrounding normal mucosa. - **Corkscrew Vessels**: - Abnormal, twisted vessels often seen in early gastric cancer, indicative of neoplastic changes. #### **2. Surface Pattern (S)** - **Irregular Microsurface Structure**: - Loss of normal pit patterns. - Presence of irregular, ridged, or nodular mucosal surface architecture. - **White Zone Changes**: - Areas of abnormal light reflection, suggesting mucosal damage or cancerous transformation. --- ### **Diagnostic Criteria** Early gastric cancer (EGC) is suspected when: 1. **Vascular Pattern**: - Irregular microvascular architecture is observed. - A distinct **demarcation line** separates the lesion from normal mucosa. 2. **Surface Pattern**: - Irregular microsurface structure is present. - **White zone changes** are visible. When **both vascular and surface irregularities** are identified, the likelihood of EGC is significantly increased. --- ### **Clinical Applications** 1. **Targeted Biopsy**: - The VS system helps identify suspicious areas for biopsy, improving diagnostic accuracy and reducing unnecessary biopsies. 2. **Endoscopic Submucosal Dissection (ESD)**: - Lesions diagnosed using the VS system can be resected precisely via ESD, ensuring complete removal with clear margins. 3. **Surveillance**: - High-risk patients (e.g., those with chronic atrophic gastritis or intestinal metaplasia) can be monitored using the VS system to detect EGC at an early stage. --- ### **Advantages of the VS Classification System** 1. **High Sensitivity and Specificity**: - Improves diagnostic accuracy compared to conventional white light endoscopy (WLE). - Sensitivity: ~88%; Specificity: ~75% (depending on study and operator expertise). 2. **Non-Invasive**: - NBI is integrated into standard endoscopy systems, eliminating the need for dyes or additional equipment. 3. **Improved Diagnostic Yield**: - Enhances the detection of subtle mucosal changes indicative of early gastric cancer. --- ### **Limitations** 1. **Operator Dependence**: - Requires expertise in magnifying NBI and familiarity with VS classification patterns. 2. **False Positives**: - Inflammatory lesions or benign changes may mimic irregular vascular and surface patterns, leading to potential overdiagnosis. --- ### **Comparison: VS Classification vs White Light Endoscopy (WLE)** | **Parameter** | **VS Classification (NBI)** | **White Light Endoscopy (WLE)** | |------------------------------|--------------------------------------|-----------------------------------------| | **Vascular Visualization** | Enhanced with high contrast | Limited visualization | | **Surface Architecture** | Detailed microsurface pattern | Poor resolution of surface patterns | | **Diagnostic Accuracy** | Higher sensitivity and specificity | Lower sensitivity for early lesions | | **Targeted Biopsy** | Precise biopsy sampling | Random biopsy sampling | --- ### **Clinical Evidence Supporting VS Classification** 1. **Ezoe et al. (2011)**: - Demonstrated that magnifying NBI with the VS system was more accurate than WLE for diagnosing gastric mucosal cancer. - Sensitivity: 88%; Specificity: 75%. 2. **Zhang et al. (2016)**: - A meta-analysis showed that NBI combined with the VS classification significantly improved diagnostic efficacy for EGC. 3. **Dinis-Ribeiro et al. (2017)**: - Prospective studies confirmed that the VS system reduces unnecessary biopsies while maintaining high diagnostic accuracy. --- ### **Future Directions** 1. **Artificial Intelligence (AI)**: - AI algorithms are being developed to automate the VS classification process, reducing operator dependency and enhancing diagnostic precision. 2. **Training Programs**: - Structured training for endoscopists to improve proficiency in recognizing VS patterns and using NBI technology. 3. **Expansion to Other GI Cancers**: - The VS classification system may be adapted for diagnosing other gastrointestinal cancers, such as esophageal or colorectal neoplasms. --- ### **Summary** The **VS Classification System** is a powerful tool for diagnosing **early gastric cancer (EGC)** using **Narrow Band Imaging (NBI)**. By evaluating **vascular patterns** (irregular microvascular architecture, demarcation line) and **surface patterns** (irregular microsurface structure, white zone changes), the system provides high sensitivity and specificity for early cancer detection. It facilitates **targeted biopsies**, improves diagnostic accuracy, and supports precise therapeutic interventions like **endoscopic submucosal dissection (ESD)**. Despite its operator dependency, the VS system represents a significant advancement in endoscopic imaging, offering the potential for earlier detection and better outcomes in gastric cancer management.